Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism.

Winer KK, Fulton KA, Albert PS, Cutler GB Jr

The Journal of pediatrics16 Jun 2014Cited by 83 (Europe PMC)

PMID24948345PMCIDPMC4174419DOI10.1016/j.jpeds.2014.04.060PepBankPUB-24948345

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In children with congenital hypoparathyroidism, pump-delivered PTH 1‑34 increased mean serum calcium versus twice-daily injection toward normal values.
In plain wordsIn children with congenital hypoparathyroidism, pump-delivered PTH 1‑34 increased blood calcium toward normal values compared with twice-daily injection.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMean serum calcium
Study
n = 12
Comparator
Twice-daily subcutaneous PTH 1-34 injection
Analysis
Primary
Outcome group
Electrolyte balance · Endocrine and hormones
Measurements
Mean serum calcium
2.02 mmol/L
pump
Mean serum calcium
1.88 mmol/L
twice-daily injection
Source sentences
Summary
PTH 1-34 delivered via pump produced near normalization of mean serum calcium (2.02 ± 0.05 [pump] vs 1.88 ± 0.03 [injection] mmol/L, P < .05, normal 2.05-2.5 mmol/L)
1 context sentence(design, population, supporting numbers)
Summary · context
Children and young adults aged 7-20 years with congenital hypoparathyroidism (N = 12) were randomized to receive PTH 1-34, delivered either by twice-daily subcutaneous injection or insulin pump for 13 weeks, followed by crossover to the opposite delivery method.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2494834501
02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In children with congenital hypoparathyroidism, pump-delivered PTH 1‑34 normalized mean urine calcium, without a significant difference versus twice-daily injection.
In plain wordsIn children with congenital hypoparathyroidism, mean urine calcium with pump-delivered PTH 1‑34 did not significantly differ from twice-daily injection.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeUrine calcium excretion
Study
n = 12
Comparator
Twice-daily subcutaneous PTH 1-34 injection
Analysis
Primary
Outcome group
Electrolyte balance · Endocrine and hormones
Measurements
Mean urine calcium excretion
5.17 mmol/24 h/1.73 m(2)
pump
Mean urine calcium excretion
6.67 mmol/24 h/1.73 m(2)
twice-daily injection
Source sentences
Summary
normalized mean urine calcium excretion (5.17 ± 1.10 [pump] vs 6.67 ± 0.76 mmol/24 h/1.73 m(2), P = .3)
1 context sentence(design, population, supporting numbers)
Summary · context
Children and young adults aged 7-20 years with congenital hypoparathyroidism (N = 12) were randomized to receive PTH 1-34, delivered either by twice-daily subcutaneous injection or insulin pump for 13 weeks, followed by crossover to the opposite delivery method.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2494834502
03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In children with congenital hypoparathyroidism, serum calcium showed minimal fluctuation with pump PTH 1‑34 versus a biphasic pattern with twice-daily injection.
In plain wordsIn children with congenital hypoparathyroidism, blood calcium fluctuated less with pump PTH 1‑34 than with twice-daily injection.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum calcium fluctuation
Study
n = 12
Comparator
Twice-daily subcutaneous PTH 1-34 injection
Analysis
Primary
Outcome group
Electrolyte balance · Endocrine and hormones
Source sentences
Summary
Serum and urine calcium and magnesium showed a biphasic pattern during twice-daily injection vs minimal fluctuation during pump delivery.
1 context sentence(design, population, supporting numbers)
Summary · context
Children and young adults aged 7-20 years with congenital hypoparathyroidism (N = 12) were randomized to receive PTH 1-34, delivered either by twice-daily subcutaneous injection or insulin pump for 13 weeks, followed by crossover to the opposite delivery method.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2494834504
04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In children with congenital hypoparathyroidism, urine calcium showed minimal fluctuation with pump PTH 1‑34 versus a biphasic pattern with twice-daily injection.
In plain wordsIn children with congenital hypoparathyroidism, urine calcium fluctuated less with pump PTH 1‑34 than with twice-daily injection.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseUrine calcium fluctuation
Study
n = 12
Comparator
Twice-daily subcutaneous PTH 1-34 injection
Analysis
Primary
Outcome group
Electrolyte balance · Endocrine and hormones
Source sentences
Summary
Serum and urine calcium and magnesium showed a biphasic pattern during twice-daily injection vs minimal fluctuation during pump delivery.
1 context sentence(design, population, supporting numbers)
Summary · context
Children and young adults aged 7-20 years with congenital hypoparathyroidism (N = 12) were randomized to receive PTH 1-34, delivered either by twice-daily subcutaneous injection or insulin pump for 13 weeks, followed by crossover to the opposite delivery method.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2494834505
05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In children with congenital hypoparathyroidism, pump-delivered PTH 1‑34 reduced bone turnover markers versus twice-daily injection.
In plain wordsIn children with congenital hypoparathyroidism, pump-delivered PTH 1‑34 reduced bone turnover markers compared with twice-daily injection.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBone turnover markers
Study
n = 12
Comparator
Twice-daily subcutaneous PTH 1-34 injection
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
and significantly reduced markers of bone turnover (P < .02).
1 context sentence(design, population, supporting numbers)
Summary · context
Children and young adults aged 7-20 years with congenital hypoparathyroidism (N = 12) were randomized to receive PTH 1-34, delivered either by twice-daily subcutaneous injection or insulin pump for 13 weeks, followed by crossover to the opposite delivery method.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2494834503
06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In children with congenital hypoparathyroidism, serum magnesium showed minimal fluctuation with pump PTH 1‑34 versus a biphasic pattern with twice-daily injection.
In plain wordsIn children with congenital hypoparathyroidism, blood magnesium fluctuated less with pump PTH 1‑34 than with twice-daily injection.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum magnesium fluctuation
Study
n = 12
Comparator
Twice-daily subcutaneous PTH 1-34 injection
Analysis
Secondary
Outcome group
Electrolyte balance · Endocrine and hormones
Source sentences
Summary
Serum and urine calcium and magnesium showed a biphasic pattern during twice-daily injection vs minimal fluctuation during pump delivery.
1 context sentence(design, population, supporting numbers)
Summary · context
Children and young adults aged 7-20 years with congenital hypoparathyroidism (N = 12) were randomized to receive PTH 1-34, delivered either by twice-daily subcutaneous injection or insulin pump for 13 weeks, followed by crossover to the opposite delivery method.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2494834506
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In children with congenital hypoparathyroidism, urine magnesium showed minimal fluctuation with pump PTH 1‑34 versus a biphasic pattern with twice-daily injection.
In plain wordsIn children with congenital hypoparathyroidism, urine magnesium fluctuated less with pump PTH 1‑34 than with twice-daily injection.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseUrine magnesium fluctuation
Study
n = 12
Comparator
Twice-daily subcutaneous PTH 1-34 injection
Analysis
Secondary
Outcome group
Electrolyte balance · Endocrine and hormones
Source sentences
Summary
Serum and urine calcium and magnesium showed a biphasic pattern during twice-daily injection vs minimal fluctuation during pump delivery.
1 context sentence(design, population, supporting numbers)
Summary · context
Children and young adults aged 7-20 years with congenital hypoparathyroidism (N = 12) were randomized to receive PTH 1-34, delivered either by twice-daily subcutaneous injection or insulin pump for 13 weeks, followed by crossover to the opposite delivery method.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2494834507
08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In children with congenital hypoparathyroidism, pump delivery reduced PTH 1‑34 dosage versus twice-daily injection.
In plain wordsIn children with congenital hypoparathyroidism, pump delivery required less PTH 1‑34 than twice-daily injection.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePTH dosage requirement
Study
n = 12
Comparator
Twice-daily subcutaneous PTH 1-34 injection
Outcome group
Patterns of use · Endocrine and hormones
Measurements
PTH dosage
0.32 μg/kg/d
pump
PTH dosage
0.85 μg/kg/d
twice-daily injection
Source sentences
Summary
The PTH 1-34 dosage was markedly reduced during pump delivery (0.32 ± 0.04 vs 0.85 ± 0.11 μg/kg/d, P < .001), and magnesium supplements were also reduced (P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
Children and young adults aged 7-20 years with congenital hypoparathyroidism (N = 12) were randomized to receive PTH 1-34, delivered either by twice-daily subcutaneous injection or insulin pump for 13 weeks, followed by crossover to the opposite delivery method.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2494834508
09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement
In children with congenital hypoparathyroidism, pump-delivered PTH 1‑34 reduced magnesium supplement requirements versus twice-daily injection.
In plain wordsIn children with congenital hypoparathyroidism, pump-delivered PTH 1‑34 reduced magnesium supplement needs compared with twice-daily injection.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseMagnesium supplement requirement
Study
n = 12
Comparator
Twice-daily subcutaneous PTH 1-34 injection
Outcome group
Electrolyte balance · Endocrine and hormones
Source sentences
Summary
The PTH 1-34 dosage was markedly reduced during pump delivery (0.32 ± 0.04 vs 0.85 ± 0.11 μg/kg/d, P < .001), and magnesium supplements were also reduced (P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
Children and young adults aged 7-20 years with congenital hypoparathyroidism (N = 12) were randomized to receive PTH 1-34, delivered either by twice-daily subcutaneous injection or insulin pump for 13 weeks, followed by crossover to the opposite delivery method.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2494834509

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00743782

Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism

National Institutes of Health Clinical Center (CC)n = 2122 Aug 2008 to 7 Apr 2014

Hypoparathyroidism · Hypocalcemia · Autoimmune Polyendocrine Syndrome Type 1 · Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Trial page ClinicalTrials.govUpdated 4 Mar 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.